Related Experiment Video
Updated: Jul 6, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
Mitigate Japan's Drug Loss With Model-Informed Drug Development
Yasuhiko Imai1, Emi Akatsu1, Suzanne K Minton2
1Certara GK, Tokyo, Japan.
Abstract:
'Drug loss' in Japan refers to drugs that have been approved and marketed overseas but haven't been developed, submitted, or approved in Japan. A comprehensive Model-Informed Drug Development (MIDD) strategy, enhanced with artificial intelligence/machine learning, can minimize drug loss. Continued pharmaceutical industry and regulatory commitment and collaboration in applying MIDD will facilitate Japanese patients' access to essential medicines and solidify Japan's role in global pharmaceutical advancement.
Related Concept Videos
Drug Discovery: Overview
Drug Regulation
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Drug Clearance: Overview
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Drug Distribution as One-Compartment Model and Elimination by Nonlinear Pharmacokinetics: Overview
For instance, consider the metabolism of sodium salicylate. This compound is metabolized into two distinct substances: a glucuronide and a glycine conjugate. The rate of conjugation depends...

